

Metabolic syndrome does not impair the response to alfuzosin treatment in men with lower urinary tract symptoms: a double-blind, randomized, placebo-controlled study

Alt üriner sistem semptomları olan erkeklerde metabolik sendrom bulunması alfuzosin tedavisine cevabı azaltmaz: çift-kör, randomize, plasebo kontrollü bir çalışma

Selçuk Altın¹, Tunç Ozan¹, Selçuk İlhan², Nevin İlhan³, Rahmi Onur¹

ABSTRACT

Objective: This study is a placebo-controlled comparison of the response to alfuzosin treatment for lower urinary tract symptoms (LUTS) in patients with and without metabolic syndrome (MetS).

Material and methods: A total of 80 men with LUTS were included in the study. Patients had a maximum flow rate of <15 mL/sec, prostate volume of >20 mL, and International Prostate Symptom Score (IPSS) of >8. All eligible men (n=68) for evaluation were initially divided into two groups as MetS (n=34) and non-MetS (n=34) groups. Patients were further randomized to receive alfuzosin (10 mg/day) or placebo (n=17/group; a total of four groups). The outcome was measured at 12th week according to the changes from baseline in IPSS, quality of life (QoL) scores, maximum flow rate (Qmax), and postmictorial residue.

Results: Alfuzosin significantly improved LUTS in men with and without MetS compared with patients receiving placebo (p<0.05). Mean IPSS scores in treatment groups decreased significantly, whereas patients receiving placebo had no statistically significant difference (p>0.05). Similarly, alfuzosin treatment resulted in a significant increase in Qmax in patients with LUTS/benign prostatic enlargement when compared with patients in placebo group (p<0.05). Mean QoL scores measured by IPSS-QoL and QoL questionnaires also improved significantly in patients receiving alfuzosin for 3 months regardless of the presence of MetS (p<0.05).

Conclusion: Our results revealed that the presence of MetS in patients with LUTS did not impair the response to alfuzosin treatment.

Keywords: Alfuzosin; lower urinary tract symptoms treatment; metabolic syndrome.

ÖZ

Amaç: Bu çalışmada; metabolik sendrom (MetS) olan ve olmayan alt üriner sistem semptomlu (AÜSS) hastalarda alfuzosin tedavisinin etkinliği plasebo kontrollü olarak incelenmesi amaçlandı.

Gereç ve yöntemler: AÜSS'si olan toplam 80 hasta çalışmaya dahil edildi. Üroflowmetrik tetkikte hastaların maksimum idrar akış hızı (@max) 15 mL/s, prostate hacmi >20 mL ve Uluslararası Prostat Semptom Skoru (IPSS) >8 şeklindeydi. Bulunan 80 hasta içinden 68 tanesi çalışmaya uygun olarak belirlendi. Çalışmaya dahil edilen hastalar (n=68) MetS (n=34) and non-MetS (n=34) gruplarına ayrıldı. Hastalara randomize bir şekilde alfuzosin (10 mg/gün) veya plasebo (n=17/grup, toplam 4 grup). Sonuçlar 12. haftada IPSS, Yaşam Kalitesi Ölçeği (YKÖ), Qmax ve post miksiyonel rezidü (PMR) parametrelerindeki değişiklikler açısından değerlendirildi.

Bulgular: Alfuzosin AÜSS üzerine MetS olan ve olmayan hastalarda plaseboya göre anlamlı oranda fayda sağladı (p<0,05). Tedavi gruplarındaki ortalama IPSS değerleri istatistiksel olarak anlamlı bir şekilde azalırken, bu azalma plasebo kullanan gruplarda anlamlı olmadı (p>0,05). Bu duruma benzer olarak alfuzosin tedavisi AÜSS olan hastalarda Qmax açısından anlamlı artış sağladı (p<0,05). IPSS-YKÖ ve YKÖ ile yapılan ölçümlerde alfuzosin kullanan hastalarda ortalama YK skorları MetS olsun olmasın alfuzosin tedavisi alan hastalarda 3. ayda anlamlı olarak artmış bulundu (p<0,05).

Sonuç: Çalışmamızda AÜSS'ı olan hastalarda MetS'un alfuzosin tedavisine yanıtı bozmadığı gözlenmiştir.

Anahtar kelimeler: Alfuzosin; alt üriner sistem semptomlarının tedavisi; metabolik sendrom.

¹Department of Urology, Firat University Faculty of Medicine, Elazığ, Turkey

²Department of Pharmacology, Firat University Faculty of Medicine, Elazığ, Turkey

³Department of Biochemistry, Firat University Faculty of Medicine, Elazığ, Turkey

Submitted:
05.03.2015

Accepted:
25.03.2015

Correspondence:
Tunç Ozan,
E-mail: drtuncozan@yahoo.com

©Copyright 2015 by Turkish Association of Urology

Available online at
www.turkishjournalofurology.com

Introduction

Metabolic syndrome (MetS) has been considered to have an important role in the development or progression of lower urinary tract symptoms (LUTS) and/or benign prostatic enlargement (BPE).^[1, 2] The incidence of LUTS was reported to be significantly higher in patients with MetS, which increases the evidence of a relationship between the presence of MetS and LUTS.^[1-3] The pathophysiology of LUTS is not limited to benign prostatic hyperplasia (BPH) and it is rather multifactorial. Chronic diseases, such as diabetes, cardiac pathologies or lifestyle changes, and components of MetS, such as insulin resistance (IR), obesity, and hyperlipidemia, may lead to the development or progression of LUTS.^[4-6]

A possible link between LUTS and MetS may be accompanied by IR.^[7] Hyperinsulinemia, the core pathophysiology of MetS, was previously shown to be associated with increased annual growth of prostate volume and increased smooth muscle tone.^[7, 8] Increased sympathetic tone caused by increased serum insulin levels in the presence of MetS has been reported to contribute to the development of LUTS in patients with BPE or BPH.^[9] Similarly, insulin-like growth factor (IGF) and chronic inflammation induced by MetS were shown to stimulate the growth of prostatic stromal and epithelial cells.^[10] Hammersten et al.^[7] examined a total of 280 men with and without hyperinsulinemia and found the median annual prostatic growth rate to be significantly higher in patients with increased insulin levels. The Third National Health and Nutrition Examination Survey conducted in men >60 years revealed that the odds of having LUTS increased significantly in men with three or more components of MetS.^[2] Similarly, in a community-based healthy survey, a trend in the increasing prevalence of MetS with increasing American Urological Association Symptom Index (AUA-SI) was observed.^[11]

Currently, the standard pharmacological treatment for men with LUTS is alpha (α)-adrenergic receptor blockers.^[12] Indirect and limited direct comparisons between different α -blockers revealed that all α -blockers have similar efficacy in therapeutic doses.^[13] However, there is limited data regarding the efficacy of α -blocker use in the treatment of patients with concomitant LUTS and MetS. In this double-blind, randomized, and placebo-controlled study, we aimed to evaluate the response to alfuzosin treatment for LUTS in patients with and without MetS.

Materials and methods

Patient enrollment and study groups: The study has been reviewed by the local ethics committee for human subjects after detailed examination and is addressed by the approval number of 07/07-2.4.2011. Between May 2011 and May 2012, a total of 80 men with or without MetS having severe LUTS presented to Urology and/or Endocrinology outpatient clinics

were enrolled into the study. All patients were informed about the study protocol, and written consents were obtained. Frail elderly patients and patients with the following criteria were excluded from the study: neurogenic lower urinary tract dysfunction, previous lower urinary tract surgery, active urinary tract infection, increased prostate-specific antigen (PSA) levels (without documented pathology in biopsy), history of lower urinary tract malignancy, urethral stricture, history of previous medication for LUTS, or hormonal treatment. Uroflowmetric study (MMS Flowmaster; Earth City, MO, USA) and prostate volume measurement (Esaote Biomedica AU3 Partner Advanced Ultrasonography, Genoa, Italy) were performed. All of the enrolled patients had a maximum flow rate of <15 mL/s, prostate volume of >20 mL, and International Prostate Symptom Score (IPSS) of ≥ 8 . Patients with PSA levels of >4 ng/dL underwent biopsy and were enrolled after a negative histopathological examination.

Of the 80 patients with LUTS, 68 men were eligible to participate in the study and were randomly assigned to four equal groups. All men were first randomized according to the presence of MetS and then according to the administration of either alfuzosin 10 mg/day (Generica, Istanbul, Turkey) or placebo for 3 months. All patients were assigned a number at the beginning of the study, and each number was randomly assigned to one of the two treatment options using computed generated by GraphPad software (GraphPad Software Inc., La Jolla, CA). The study medications and placebo provided by the same company (Generica, Istanbul, Turkey) were identical in appearance to preserve blinding. The study design and patient allocation was presented in Figure 1.




Figure 1. Study design and randomization of patients

¹Lower urinary tract symptoms, ²Metabolic syndrome

Assessment of LUTS and diagnosis of MetS: Detailed physical and neurological examinations and laboratory assessment were performed for all patients; inspection and palpation of the organs belonging to the system including the digital rectal examination of the prostate was performed. Sensations and reflexes in the urogenital area have been tested. The anal sphincter and pelvic floor functions must be extensively tested. The symptoms and their effects on quality of life (QoL) were evaluated by IPSS and disease-specific QoL question score from IPSS, respectively, as described previously. IPSS was used to assess the degree of severity of LUTS. Each symptom is graded from 0 (not at all) to 5 (almost always), and the scores of each individual symptom were added to reach the total score of 35. Urinary flow rate and post-void residual urine measurements (Esaote Biomedica AU3 Partner Advanced Ultrasonography, Genoa, Italy) were performed in all patients both prior to and at the end of the study (3 months).

Blood pressure, body weight, body height, waist/hip circumferences, and body mass index (BMI) were measured in all men. Biochemical analyses including glucose and lipid profiles and PSA levels were measured using spectrophotometric (Siemens Advia 2400; Healthcare Dgn., Tarrytown, NY, USA) and chemiluminescence methods (Siemens Advia Centaur XP, Healthcare Dgn., Tarrytown, NY, USA), respectively.

Diagnosis of MetS was made according to the most recent consensus report of the National Cholesterol Education Program's Third Adult Treatment Panel (NCEP ATP III).^[2] The diagnostic criteria for MetS had to satisfy three or more of the NCEP-ATP III criteria, which are as follows:

1) hypertension (blood pressure of $\geq 130/85$ mmHg); 2) hyperglycemia (fasting blood glucose level of ≥ 110 mg/dL); 3) abdominal obesity (waist circumference of >102 cm); 4) hypertriglyceridemia (serum triglyceride (TG) levels of ≥ 150 mg/dL); and 5) reduced levels of high-density lipoprotein (HDL) cholesterol (<40 mg/dL).

The primary outcome measures examined in our study were the percentage of changes in IPSS and maximum flow rates. Secondary measures were QoL scores and change in postmicturitional residue (PVR). All patients were evaluated at 4th and 8th week for any side-effects and compared at the end of 12th week.

Statistical analysis

All data were presented as mean \pm standard deviation. Statistical analyses were performed using the Statistical Package of the Social Sciences (SPSS) 10 software (Chicago, IL, USA). Comparisons of parameters between the groups at baseline and after 3 months of treatment were performed using Kruskal Wallis and Mann Whitney U-tests, and the efficacy of treatment was assessed by the Wilcoxon test within the groups. A p value of <0.05 was considered to be statistically significant.

Results

The demographic data and laboratory findings of men in the study groups were shown in Table 1. Mean age of the patients was 64.18 ± 7.61 (50–84). There was no significant difference between groups with respect to age, prostate volume, and PSA ($p>0.05$). Similarly, baseline IPSS, mean QoL scores, maximum flow rate (Qmax), and PVR measurements showed no significant differ-

Table 1. Patient demographics and laboratory findings of each group

	MetS+alfuzosin (Group 1)	MetS+placebo (Group 2)	Alfuzosin (Group 3)	Placebo (Group 4)
Age	63.94 \pm 6.05	66.88 \pm 7.45	65.67 \pm 9.68	60.18 \pm 5.21
T PSA (ng/mL)	0.9 \pm 2.37	1.9 \pm 1.10	1.67 \pm 1.25	1.07 \pm 1.23
HDL (mg/dL)	46.23 \pm 12.87 ^{a,b}	41.88 \pm 6.20 ^{a,b}	49.27 \pm 16.45	50.00 \pm 9.42
BMI (kg/m ²)	31.20 \pm 3.55 ^{a,b}	30.01 \pm 4.26 ^{a,b}	25.94 \pm 3.04	27.04 \pm 3.26
Waist circumference (cm)	110 \pm 5.09 ^{a,b,c}	103 \pm 8.46 ^{a,b}	90 \pm 6.45	90 \pm 11.17
Body weight (kg)	90 \pm 10.40 ^{a,b}	86 \pm 10.50 ^{a,b}	77 \pm 10.20	78 \pm 10.06
HbA1c	9.6 \pm 2.14 ^{a,b}	8 \pm 2.40 ^{a,b}	5.4 \pm 1.00	4.9 \pm 1.20
IPSS	18.24 \pm 6.39	17.82 \pm 5.92	17.67 \pm 5.92	18.18 \pm 6.26
Qmax (mL/sn)	12.19 \pm 2.13	12.51 \pm 2.59	10.59 \pm 2.63	13.26 \pm 1.71
PVR (mL)	54.59 \pm 26.64	43.71 \pm 29.24	43.78 \pm 30.55	45.88 \pm 32.76

Data are presented as mean \pm SD.

a, Statistically significant difference compared with placebo group ($p<0.05$)

b, Statistically significant difference compared with alfuzosine group

c, Statistically significant difference compared with MetS+placebo group

PSA: prostate-specific antigen; MetS: metabolic syndrome; HDL: high density lipoprotein; BDI: body mass index; IPSS: international prostate symptom score; Qmax: maximum flow rate; PVR: post-voiding residue

Table 2. Assessment of primary and secondary outcome measures before (BT) and after (AT) treatment in each group

	MetS+alfuzosin (Group 1)	MetS+placebo (Group 2)	Alfuzosin (Group 3)	Placebo (Group 4)
IPSS BT	18.24±6.39	17.82±5.92	17.67±9.92	18.18±6.26
IPSS AT	11.53±8.35 ^{a,c,d}	16.06±6.99 ^b	12.50±6.36 ^{a,d}	14.18±7.89
IPSS-QoL BT	3.47±0.71	3.59±0.62	3.44±0.62	3.59±0.62
IPSS-QoL AT	2.65±0.79 ^d	3.18±0.95	2.72±0.83 ^d	3.29±0.95
BPH-QoL				
BT	16.53±11.54	18.88±6.72 ^b	12.78±6.65	15.71±10.91
BPH-QoL AT	9.65±12.26 ^{c,d}	16.94±7.62 ^b	7.06±6.37 ^{c,d}	12.18±10.82
Qmax (mL/s) BT	12.19±2.13	12.51±2.59 ^b	10.59±2.63 ^a	13.26±1.71
Qmax (mL/s) AT	16.25±5.48 ^{c,d}	12.12±3.32	13.32±3.33 ^d	12.96±3.24
PVR (mL) BT	54.59±26.64	43.71±29.24	43.78±30.55	45.88±32.76
PVR (mL) AT	57.65±35.33	41.18±20.80	47.11±30.99	42.76±27.97

Data are presented as mean±SD
a, Statistically significant difference compared to placebo group
b, Statistically significant difference compared to alfuzosine group
c, Statistically significant difference compared to MetS+placebo group
d, Statistically significant difference compared to before treatment scores; p<0.05
MetS: metabolic syndrome; IPSS: international prostate symptom score; IPSS-QoL: international prostate symptom score-quality of life; BPH-QoL: benign prostate hypertrophy-quality of life; Qmax: maximum flow rate; PVR: post-voiding residue

Table 3. Percent changes ($\Delta\%$) of primary outcome measures after 12 weeks of treatment among each group

	MetS+ alfuzosin group 1	MetS+ placebo group 2	Alfuzosin group 3	Placebo group 4
Percent change of IPSS ($\Delta\%$)	-37.77% ^{a,b,c}	-9.8%	-27.89% ^{a,c}	-19.58%
Percent change of Qmax ($\Delta\%$)	+32.82% ^{a,c}	+2.25%	+30.10% ^{a,c}	+2.67%

Data are presented as mean±SD
a, Statistically significant difference compared to placebo group
b, Statistically significant difference compared to alfuzosine group
c, Statistically significant difference compared to MetS+placebo group; p<0.05
MetS: metabolic syndrome; IPSS: international prostate symptom score; Qmax: maximum flow rate

ence among each group ($p>0.05$). However, men with MetS in groups 1 and 2 had significantly higher serum levels of TG, HDL, and HbA1c compared with groups 3 and 4 ($p<0.05$). Patients with MetS in groups 1 and 2 also had significantly higher BMI, waist circumference, body weight, and blood pressure measurements than those of the patients in group 3 and 4 ($p<0.05$) (Table 1).

After 3 months of 10-mg alfuzosin treatment, LUTS in patients with and without MetS showed significant improvement compared with patients receiving placebo (groups 2 and 4; $p<0.05$). Mean IPSS scores in groups 1 and 3 increased significantly

compared with pre-treatment levels, whereas patients receiving placebo had no statistically significant difference in the IPSS scores ($p<0.05$) (Table 2). The improvement of mean IPSS in the group of patients with MetS was similar to the improvement observed in the group of patients without MetS. The percentage change in primary outcome measures (mean IPSS and Qmax scores) in all groups were -37%, -9.8%, -7.8%, and -19%, respectively (Table 3). The most significant improvement was observed in patients with MetS who received alfuzosin treatment ($p<0.05$). Post-void residual urine measurements before and after treatment were not significantly different between the groups ($p<0.05$) (Table 2).

Mean QoL scores measured by IPSS-QoL and BPH-QoL questionnaires also improved significantly in patients receiving alfuzosin for 3 months, regardless of the presence or absence of MetS ($p<0.05$). However, mean QoL scores of patients did not show any difference in patients receiving placebo compared with pre-treatment scores ($p>0.05$).

Discussion

The prevalence of MetS varies in different parts of the world. The prevalence of MetS was reported as 21.7%, 36.3%, and 17.9% in China, Jordan, and Greenland, respectively.^[14-16] Athyros et al.^[17] reviewed its prevalence in Greece and found it in 23.6% of the population. Our study was conducted in Turkey, which is considered as minor Asia or Anatolia. Kozan et al.^[18] reported the prevalence of MetS in Turkey as 33.9%, whereas in another study conducted by Ozsahin et al.^[19] it was detected as

33.4%. Several studies have suggested an increased association between LUTS and the presence of MetS in men.^[3] NCEP-ATP III showed the relationship between the markers of MetS and LUTS defined as having three of four urinary symptoms (such as nocturia, incomplete voiding, weak stream, and hesitancy).^[2] In a community-based survey analysing 1899 men, increased odds of MetS were observed even with mild symptoms, primarily for incomplete emptying, intermittency, and nocturia.^[11] The association of weight gain, increased BMI, and LUTS supports the major role of insulin-mediated effect on LUTS development and increased levels of tissue growth factors for prostate enlargement.^[20] Another hypothesis for the increased detection of LUTS in men with MetS is atherosclerosis of pelvic vessels and subsequent chronic pelvic ischemia of the bladder and prostate.^[21] Alternatively, the inflammatory molecules, such as C-reactive proteins, or impaired endothelium-derived nitric oxide pathway may be the mediators of intraprostatic inflammation, thereby contributing to LUTS development.^[22, 23] However, the most important pathophysiological event for the development of LUTS in men with BPH was reported to be IR and compensatory hyperinsulinemia, which induces autonomic hyperactivity.^[24] Subsequent unbalanced loss of autonomic neurons was suggested to induce an oversupply of sympathetic tone over parasympathetic tone, resulting in increased bladder neck obstruction.^[25]

Lower urinary tract symptoms secondary to BPH are primarily treated by α -adrenergic blockers, which aim to lower the sympathetic tone and increase urinary flow rate. By inhibiting smooth muscle α -adrenergic receptors, the drugs relax prostatic and bladder neck smooth muscles and partially improve LUTS by relieving bladder outlet obstruction.^[26] Although α -blockers have a proven role for the symptomatic treatment of LUTS, there is little evidence about their efficacy for the treatment of LUTS in men with MetS. Gökkaya et al.^[27] prospectively evaluated the effects of IR on the outcomes of doxazosin treatment for LUTS in 64 patients. Doxazosin treatment significantly lowered the mean IPSS levels and increased Qmax in men without IR, whereas this treatment did not affect the mean IPSS and Qmax. Authors concluded that IR impaired the response to doxazosin treatment for LUTS caused by BPH. However, the similar pre- and post-treatment values of IPSS and Qmax in patients with improved and non-improved IR in that study suggested that the disappearance of IR after doxazosin had no impact on the outcomes of BPH therapy. They commented that this result was related to their patients' high baseline homeostasis model assessment (HOMA) scores, shorter duration of treatment, and differences in patient profile. In addition to these limitations, the study also had no placebo arm. In a recent study evaluating the responsiveness to α 1-blocker treatment in men with concomitant LUTS and MetS, Lee et al.^[28] examined the efficacy of 4-mg doxazosin GITS administered once daily in 109 patients. After 12 weeks of drug treatment, the respon-

ers were defined as those having a decrease in the total IPSS by >4 points from baseline. Sixty-six percent of the patients responded to α 1-blocker treatment, and multivariate analysis revealed that MetS was significantly higher in the non-responder group. Similarly, IPSS improvements from baseline in patients with MetS significantly decreased as the number of MetS components increased. Thus, the authors concluded that MetS may lead to a different drug response than that expected and α -blocker treatment with the aim of interrupting sympathetic adrenergic activity may not produce the desired treatment efficacy. Despite these findings, authors acknowledged that because of the lack of molecular investigations, their study did not provide further evidence about the possible mechanisms on how MetS influenced the responsiveness to α 1-blocker therapy in men with BPH/LUTS.^[28]

Our randomized, placebo-controlled study revealed that alfuzosin was similarly effective, regardless of the presence or absence of MetS in men with BPH. In a recent study examining the association between MetS, hyperinsulinemia, and LUTS, Eom et al.^[29] found that voiding symptoms were decreased in men with MetS compared with men without MetS. However, LUTS had a strong, positive, and significant association when they were present at a severe level of metabolic derangement (HbA1c level of $\geq 8\%$). We measured serum HbA1c levels of $\geq 8\%$ in patients with MetS; however, we randomized the patients with similar IPSS scores into groups to prevent a potential bias of selection. On the contrary, Roehrborn et al.^[26] found a close association of MetS components with LUTS in older men, whereas Joseph et al.^[30] detected that hypertension or diabetes mellitus were at a risk of moderate-to-severe LUTS. However, in a recent survey, a significant positive association was not found between MetS or IR and LUTS in men or women.^[31] Similarly, Park et al.^[32] showed no significant differences in voiding symptoms between MetS and non-MetS patients. Age, duration of the components of MetS, HbA1c level, and long-term hyperglycemia were all reported to have either favorable or unfavorable effects on LUTS.^[29] The glomerular filtration and insulin are commonly increased in early diabetes, and these early compensatory mechanisms may favorably affect LUTS; however, with time the decreased glomerular filtration and advanced diabetes may worsen different components of LUTS.^[2, 3] Thus, considering the controversial data regarding relationship between LUTS and MetS, it cannot be concluded that MetS may or may not worsen LUTS everytime. Similarly, it cannot always be stated that there will be poor responsiveness to α 1-blocker therapy in men with LUTS and concomitant MetS. To our knowledge, our study is the first to provide a similar response to alfuzosin in men with BPH and MetS compared with the response obtained in men without MetS.

In the Korean Longitudinal Study on Health and Aging, there was no significant change in the IPSS between the metabolic




Figure 2. Percent changes of IPSS, IPSS-QoL, BPH-QoL, Qmax and PVR in the study groups

and non-metabolic groups. We also detected no significant difference between the groups in the pretreatment period with respect to IPSS and QoL scores. After 12 weeks of the treatment period, IPSS significantly decreased whereas QoL improved in groups 1 and 3 compared with placebo groups. According to the AUA guidelines, α -blockers provide four- to six-point decrease in AUA symptoms score.^[33] In our study, we detected a 6.7 (-37.7%) and 5.1 (-27.8%) IPSS improvement in Group 1 and Group 3, respectively. The highest change in the percentage of IPSS and IPSS-QoL score was recorded in men with MetS patients receiving alfuzosin (groups 1 and 3; Figure 2). This improvement may be explained by the favorable effects of MetS on LUTS, which has been previously described in some studies. In a recent study conducted on 707 men with and without MetS, it was shown that men with MetS had significantly lower IPSS and better Qmax levels.^[34] Similarly, in another large series examining 33481 patients, it was reported that MetS and accompanying hyperinsulinemia could have a positive effect on voiding symptoms, particularly in the early compensatory stage.^[29]

The present study is one of the limited clinical examples to the relationship between MetS and responsiveness of α -blocker treatment in men with BPH. However, we have to acknowledge some of the limitations of our study. First, we could only enroll a relatively small group of patients. The subject population came from a single institution, but this group had well-defined symptoms evaluated by self-administered and validated questionnaires. Sample size was intended to be prospectively determined. Because we examined a specific group of patients, a total of 20 patients with MetS and LUTS demanding treatment could be recruited to receive alfuzosin. Similarly, other groups

were maintained with similar numbers. Secondly, we did not assess the degree of response to alfuzosin therapy with regard to the duration of MetS nor to the level of HbA1c. Men with MetS in our study group had mean HbA1c levels of $\geq 8.8 \pm 2.27$, which may introduce a selection bias or a potential for a response bias.

In conclusion, our data suggested that the presence of MetS in men with BPH did not impair the response to alfuzosin treatment, and patients' symptoms and QoL parameters showed similar improvements. However, our results need to be confirmed with further studies.

Ethics Committee Approval: Ethics committee approval was obtained.

Informed consent: Written informed consent was obtained from patient/patients who participated in this study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - R.O., S.A.; Design - R.O., S.A.; Supervision - R.O., T.O.; Funding - R.O., S.A.; Materials - N.İ.; Data Collection and/or Processing - S.A.; Analysis and/or Interpretation - T.O., R.O.; Literature Review - T.O.; Writer - R.O.; Critical Review - T.O., R.O.; Other - S.İ.

Conflict of Interest: The authors declared no conflict of interest.

Financial Disclosure: The authors declared that this study has received no financial support.

Etik Komite Onayı: Bu çalışma için etik komite onayı alınmıştır.

Hasta Onamı: Yazılı hasta onamı bu çalışmaya katılan hastalardan alınmıştır.

Hakem Değerlendirmesi: Dış bağımsız.

Yazar Katkıları: Fikir - R.O., S.A.; Tasarım - R.O., S.A.; Denetleme - R.O., T.O.; Kaynaklar - R.O., S.A.; Malzemeler - N.İ.; Veri toplanması ve/veya işlemesi - S.A.; Analiz ve/veya yorum - T.O., R.O.; Literatür taraması - T.O.; Yazıyı yazan - R.O.; Eleştirel İnceleme - T.O., R.O.; Diğer - S.İ.

Çıkar Çatışması: Yazarlar çıkar çatışması bildirmemişlerdir.

Finansal Destek: Yazarlar bu çalışma için finansal destek almadıklarını beyan etmişlerdir.

References

1. Kasturi S, Russell S, McVary KT. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Curr Urol Rep* 2006;7:288-92. [Crossref]
2. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). *Int J Obes (Lond)* 2005;29:310-6. [Crossref]

3. Moul S, McVary KT. Lower urinary tract symptoms, obesity and the metabolic syndrome. *Curr Opin Urol* 2010;20:7-12. [\[Crossref\]](#)
4. Fitzgerald MP, Link CL, Litman HJ, Trivison TG, McKinlay JB. Beyond the lower urinary tract: the association of urologic and sexual symptoms with common illnesses. *Eur Urol* 2007;52:407-15. [\[Crossref\]](#)
5. Joseph MA, Harlow SD, Wei JT, Sarma AV, Dunn RL, Taylor JM, et al. Risk factors for lower urinary tract symptoms in a population based sample of African-American men. *Am J Epidemiol* 2003;157:906-7. [\[Crossref\]](#)
6. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. *J Urol* 2000;163:1725-9. [\[Crossref\]](#)
7. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. *Eur Urol* 2001;39:151-8. [\[Crossref\]](#)
8. Hammarsten J, Damber JE, Karlsson M, Knutson T, Ljunggren O, Ohlsson C, et al. Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. *Prostate Cancer Prostatic Dis* 2009;12:160-5. [\[Crossref\]](#)
9. Vikram A, Jena G, Ramarao P. Insulin-resistance and benign prostatic hyperplasia: the connection. *Eur J Pharmacol* 2010;641:75-81. [\[Crossref\]](#)
10. Peehl DM, Cohen P, Rosenfeld RG. The role of insulin-like growth factors in prostate biology. *J Androl* 1996;17:2-4.
11. Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, et al. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. *J Urol* 2009;182:616-24. [\[Crossref\]](#)
12. Chung MS, Lee SH, Park KK, Yoo SJ, Chung BH. Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomized study. *Int J Clin Pract* 2011;65:1193-9. [\[Crossref\]](#)
13. Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha-1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. *Urology* 2004;64:1081-8. [\[Crossref\]](#)
14. Yu R, Yau F, Ho SC, Woo J. Associations of cardiorespiratory fitness, physical activity, and obesity with metabolic syndrome in Hong Kong Chinese midlife women. *BMC Public Health* 2013;13:614. [\[Crossref\]](#)
15. Khader Y, Bateiha A, El-Khateeb M, Al-Shaikh A, Ajlouni K. High prevalence of the metabolic syndrome among Northern Jordanians. *J Diabetes Complications* 2007;21:214-9. [\[Crossref\]](#)
16. Jørgensen ME, Bjerregaard P, Gyntelberg F, Borch-Johnsen K. Greenland Population Study. Prevalence of the metabolic syndrome among the Inuit in Greenland. A comparison between two proposed definitions. *Diabet Med* 2004;21:1237-42. [\[Crossref\]](#)
17. Athyros VG, Bouloukos VI, Pehlivanidis AN, Papageorgiou AA, Dionysopoulou SG, Symeonidis AN, et al. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. *Diabetes Obes Metab* 2005;7:397-405. [\[Crossref\]](#)
18. Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, et al. Prevalence of the metabolic syndrome among Turkish adults. *Eur J Clin Nutr* 2007;61:548-53.
19. Ozsahin AK, Gokcel A, Sezgin N, Akbaba M, Guvener N, Ozisik L, et al. Prevalence of the metabolic syndrome in a Turkish adult population. *Diabetes Nutr Metab* 2004;17:230-4.
20. Homer J, Jones A, Seville D, Essien J, Milstein B, Murphy D. CDC 2004a. National Health Interview Survey: Adults with Diabetes, 2002. Centers for Disease Control and Prevention, National Center for Health Statistics.
21. Shenfeld OZ, Meir KS, Yutkin V, Gofrit ON, Landau EH, Pode D. Do atherosclerosis and chronic bladder ischemia really play a role in detrusor dysfunction of old age? *Urology* 2005;65:181-4. [\[Crossref\]](#)
22. Ehren I, Iversen H, Jansson O, Adolfsson J, Wiklund NP. Localization of nitric oxide synthase activity in the human lower urinary tract and its correlation with neuroeffector responses. *Urology* 1994;44:683-7. [\[Crossref\]](#)
23. Teoh H, Verma S. C-reactive protein, metabolic syndrome, and end organ damage. *Metabolism* 2007;56:1620-2. [\[Crossref\]](#)
24. Golomb E, Rosenzweig N, Eilam R, Abramovici A. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. *J Androl* 2000;21:58-64.
25. Celtek S, Rodrigo J, Lobos E, Fernández P, Serrano J, Moncada S, et al. Selective nitroergic neurodegeneration in diabetes mellitus—a nitric oxide-dependent phenomenon. *Br J Pharmacol* 1999;128:1804-12. [\[Crossref\]](#)
26. Roehrborn CG, Rosen RC. Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. *Clin Interv Aging* 2008;3:511-24.
27. Gokkaya CS, Oztekin CV, Ozden CO, Ozturk EO, Aktas BK, Memis A. Insulin resistance impairs response to doxazosin therapy in men with benign prostatic hyperplasia. *Turk J Med Sci* 2013;43:1-5.
28. Lee YC, Liu CC, Juan YS, Wu WJ, Li WM, Yeh HC, et al. The impact of metabolic syndrome on the responsiveness to alpha-1-blocker in men with BPH/LUTS. *Int J Clin Pract* 2013;67:356-62. [\[Crossref\]](#)
29. Eom CS, Park JH, Cho BL. Metabolic syndrome and accompanying hyperinsulinemia have favorable effects on lower urinary tract symptoms in a generally healthy screened population. *J Urol* 2011;186:175-9. [\[Crossref\]](#)
30. Joseph MA, Harlow SD, Wei JT, Sarma AV, Dunn RL, Taylor JM, et al. Risk factors for lower urinary tract symptoms in a population based sample of African-American men. *Am J Epidemiol* 2003;157:906-7. [\[Crossref\]](#)
31. Temml C, Obermayr R, Marszalek M, Rauchenwald M, Madersbacher S, Ponholzer A. Are lower urinary tract symptoms influenced by metabolic syndrome? *Urology* 2009;73:544-8. [\[Crossref\]](#)
32. Park HK, Lee HW, Lee KS, Byun SS, Jeong SJ, Hong SK, et al. Relationship between lower urinary tract symptoms and metabolic syndrome in a community-based elderly population. *Urology* 2008;72:556-60. [\[Crossref\]](#)
33. AUA practice guidelines committee. AUA guidelines on management of benign prostatic hyperplasia: Chapter 1: Diagnosis and treatment recommendations. *J Urol* 2003;170:530-47. [\[Crossref\]](#)
34. Yang TK, Hsieh JT, Chen SC, Chang HC, Yang HJ, Huang KH. Metabolic syndrome associated with reduced lower urinary tract symptoms in middle-aged men receiving health checkup. *Urology* 2012;80:1093-7. [\[Crossref\]](#)